在MET放大驱动的先进非小细胞肺癌 (KUNPENG) 中使用维布列提尼布:单臂,多队列,多中心,第二阶段研究
Yi-Long Wu1, Yu Yao2, Jin-Ji Yang1
1Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University, Guangzhou, China.
The Lancet. Oncology
|December 9, 2025
概括
在MET放大非小细胞肺癌 (NSCLC) 患者中,维布列提尼布表现出显著的抗瘤活性. 这种强大的MET抑制剂在先前接受治疗和未接受治疗的个体中都显示出有前途.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- MET放大是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 目前的MET抑制剂在治疗MET放大驱动的NSCLC中表现出有限的疗效.
- 维布列提尼布是一种新型,强效和选择性的MET抑制剂.
研究的目的:
- 为了评估vebreltinib的抗瘤活性和安全性.
- 在MET放大驱动的NSCLC患者中评估vebreltinib.
- 在接受化疗和未接受化疗的人群中研究vebreltinib.
主要方法:
- 第二阶段,单臂,多中心KUNPENG试验.
- 招募的MET抑制剂原始患者有先进的NSCLC和MET放大 (基因拷贝数≥6).
- 患者每天两次口服200毫克vebreltinib;主要终点是客观反应率.
主要成果:
- 分析了86名患者 (30名接受治疗,56名未接受治疗).
- 通过独立审查,客观响应率为48.8% (42/86).
- 在31%的患者中发生了3级以上的不良事件;一个死亡可能与vebreltinib有关.
结论:
- 韦布列提尼布在MET放大后的晚期NSCLC中表现出抗瘤活性.
- 这种药物对先前接受过治疗的患者和未接受过化疗的患者都有效.
- 需要进一步的研究来证实这些发现.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
426
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
426
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
